ESMO 2022 | sciencenewsnet.in

Breaking News

Out of Africa: UT Southwestern cardiologist gets to the heart of Zambia’s No. 1 health threat

Researchers report first published case of a patient with treatment-emergent neuroendocrine prostate cancer who showed a remarkable response to an anti-HER2 antibody-drug conjugate

Weight loss interventions associated with improvements in several symptoms of PCOS

Policies assuring safe practice by late-career physicians vary widely among health care organizations

Patients outside metropolitan areas often travel significantly more than 20 minutes for primary care visit

Discovery of a protein’s key role in RNA processes could improve disease treatment in humans and plants

Health Research Launches Into Orbit to Discover How Spaceflight Affects Blood

Argonne to help drive AI revolution in astronomy with new institute led by Northwestern University

Gastrointestinal Surgeon Fabrizio Michelassi, MD, FACS, Elected Chair of ACS Board of Regents

UW–Madison researchers find persistent problems with AI-assisted genomic studies

05 Nov, 2024

Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib

September 12, 2022 sarah JonasResearch Results

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial were presented today at the European Society for Medical Oncology (ESMO) Congress 2022.

HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment

September 11, 2022 sarah JonasResearch Results

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.